Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Neutral 53.1%

Neg 0% Neu 53.1% Pos 0%

Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $50.